prikaz prve stranice dokumenta Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
  Preuzmi
PDF 1.93 MB
Znanstveni rad - Izvorni znanstveni rad
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
International Journal of Molecular Sciences, 25 (2024), 7; 3992. https://doi.org/10.3390/ijms25073992
Illini, Oliver; Saalfeld, Felix Carl; Christopoulos, Petros; Duruisseaux, Michaël; Vikström, Anders; Peled, Nir; Demedts, Ingel; Dudnik, Elizabeth; Eisert, Anna; Hashemi, Sayed M. S.; Janzic, Urska; Kian, Waleed; Mohorcic, Katja; Mohammed, Saara; Silvoniemi, Maria; Rothschild, Sacha I.; Schulz, Christian; Wesseler, Claas; Addeo, Alfredo; Armster, Karin; Itchins, Malinda; Ivanović, Marija; Kauffmann-Guerrero, Diego; Koivunen, Jussi; Kuon, Jonas; Pavlakis, Nick; Piet, Berber; Sebastian, Martin; Velthaus-Rusik, Janna-Lisa; Wannesson, Luciano; Wiesweg, Marcel; Wurm, Robert; Albers-Leischner, Corinna; Aust, Daniela E.; Janning, Melanie; Fabikan, Hannah; Herold, Sylvia; Klimova, Anna; Loges, Sonja; Sharapova, Yana; Schütz, Maret; Weinlinger, Christoph; Valipour, Arschang; Overbeck, Tobias Raphael; Griesinger, Frank; Jakopović, Marko; Hochmair, Maximilian J.; Wermke, Martin Više autora...

Citiranost: ,
Scopus (2)
Citirajte ovaj rad

Illini, O., Saalfeld, F. C., Christopoulos, P., Duruisseaux, M., Vikström, A., Peled, N. ... Wermke, M. (2024). Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis. International Journal of Molecular Sciences, 25. (7). doi: 10.3390/ijms25073992

Illini, Oliver, et al. "Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis." International Journal of Molecular Sciences, vol. 25, br. 7, 2024. https://doi.org/10.3390/ijms25073992

Illini, Oliver, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, et al. "Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis." International Journal of Molecular Sciences 25, br. 7 (2024). https://doi.org/10.3390/ijms25073992

Illini, O., et al. (2024) 'Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis', International Journal of Molecular Sciences, 25(7). doi: 10.3390/ijms25073992

Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, i sur.. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis. International Journal of Molecular Sciences [Internet]. 03.04.2024. [pristupljeno 01.04.2025.];25(7). doi: 10.3390/ijms25073992

O. Illini, et al., "Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis", International Journal of Molecular Sciences, vol. 25, br. 7, Travanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:146378. [Citirano: 01.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:146378
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
AutorOliver Illini
AutorFelix Carl Saalfeld
AutorPetros Christopoulos
AutorMichaël Duruisseaux
AutorAnders Vikström
AutorNir Peled
AutorIngel Demedts
AutorElizabeth Dudnik
AutorAnna Eisert
AutorSayed M. S. Hashemi
AutorUrska Janzic
AutorWaleed Kian
AutorKatja Mohorcic
AutorSaara Mohammed
AutorMaria Silvoniemi
AutorSacha I. Rothschild
AutorChristian Schulz
AutorClaas Wesseler
AutorAlfredo Addeo
AutorKarin Armster
AutorMalinda Itchins
AutorMarija Ivanović
AutorDiego Kauffmann-Guerrero
AutorJussi Koivunen
AutorJonas Kuon
AutorNick Pavlakis
AutorBerber Piet
AutorMartin Sebastian
AutorJanna-Lisa Velthaus-Rusik
AutorLuciano Wannesson
AutorMarcel Wiesweg
AutorRobert Wurm
AutorCorinna Albers-Leischner
AutorDaniela E. Aust
AutorMelanie Janning
AutorHannah Fabikan
AutorSylvia Herold
AutorAnna Klimova
AutorSonja Loges
AutorYana Sharapova
AutorMaret Schütz
AutorChristoph Weinlinger
AutorArschang Valipour
AutorTobias Raphael Overbeck
AutorFrank Griesinger
AutorMarko Jakopović
AutorMaximilian J. Hochmair
AutorMartin Wermke
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as... Više cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade ≥3 TRAEs were reported in 38% of patients and included diarrhea (22%) and rash (8%). In 17% of patients, therapy was permanently discontinued, and two patients died due to TRAEs. Women were seven times more likely to discontinue treatment than men. In the overall cohort, the objective response rate to mobocertinib was 34% (95% CI, 24–45). The response rate in treatment-naïve patients was 27% (95% CI, 8–58). The median progression-free and overall survival was 5 months (95% CI, 3.5–6.5) and 12 months (95% CI, 6.8–17.2), respectively. The intracranial response rate was limited (13%), and one-third of disease progression cases involved the brain. Mobocertinib also showed antitumor activity following EGFR Ex20-specific therapy and vice versa. Potential mechanisms of resistance to mobocertinib included amplifications in MET, PIK3CA, and NRAS. Mobocertinib demonstrated meaningful efficacy in a real-world setting but was associated with considerable gastrointestinal and cutaneous toxicity. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Molecular Sciences
Brojčani podacivol. 25, br. 7, 3992
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms25073992
URN:NBNurn:nbn:hr:105:146378
Datum objave publikacije2024-04-03
URL dokumentahttps://www.mdpi.com/1422-0067/25/7/3992
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2025-03-06 10:19:36
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.